Akina, Inc.
West Lafayette, IN
- UEI
- WTBLC3LE13U1
- CAGE
- 3ZDR8
- Primary NAICS
- 325211 Plastics Material and Resin Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 3495 Kent Ave o100, West Lafayette, IN 47906, USA
- Website
- akinainc.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $283,778 |
| FY2025 | $0 |
| FY2024 | $272,094 |
| FY2023 | $655,810 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $283,778 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Akina, Inc., doing business as Akina Inc., is a research company located in West Lafayette, Indiana near Purdue University. Founded in 2001 by Dr. Kinam Park, Akina provides a variety of research products and services with a focus on controlled release, medicinal delivery, and biomedical applications. The company is registered as a minority-owned, for-profit, Asian-Pacific American manufacturer.
Akina, Inc. has received prime federal contract awards from the Department of Health and Human Services Food and Drug Administration (FDA). These contracts have involved the development of new analytical methods for complex long-acting injectable formulations, specifically miniaturized formulations and injectable poly(lactide-co-glycolide) (PLGA) formulations. The contracts aim to advance the FDA's regulatory science and innovation goals, as well as support product evaluation and post-market surveillance. The awards have been firm-fixed-price definitive contracts, with no set-aside designations, ranging in value from approximately $992,000 to $1.2 million.
Akina, Inc. has also received a Project Grant award from the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse. This $320,000 grant aims to develop a 3-month injectable buprenorphine microparticle formulation for treating opioid use disorder (OUD). The project utilizes Akina's expertise in PLGA microparticle technology to prepare and characterize a 300 mg 3-month injectable buprenorphine formulation, identifying key material and process factors to control the formulation's attributes. The successful completion of this Phase I project will enable Akina to advance to a larger-scale Phase II study for clinical trials and FDA approval, addressing the lack of approved 3-month or longer treatment options for OUD.
Quick answers
Is Akina, Inc. registered in SAM.gov?
Yes. Akina, Inc.'s SAM.gov registration is active through July 14, 2027.
How much has Akina, Inc. received in federal contracts?
Federal contracts obligated $1,211,682 to Akina, Inc. in fiscal years 2023 through 2027.
What is Akina, Inc.'s most recent federal award?
Akina, Inc.'s most recent federal contract award is This is a firm fixed price fornew plga analytical methods for mini-size complex long-acting injectable formulations (75F40123C00192), from Food and Drug Administration, on September 26, 2023.
On GovTribe
See Akina, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors